Universal Beteiligungs und Servicegesellschaft mbH Invests $193.34 Million in Amgen Inc. (NASDAQ:AMGN)

Universal Beteiligungs und Servicegesellschaft mbH purchased a new position in shares of Amgen Inc. (NASDAQ:AMGN - Free Report) during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund purchased 741,785 shares of the medical research company's stock, valued at approximately $193,339,000. Universal Beteiligungs und Servicegesellschaft mbH owned approximately 0.14% of Amgen at the end of the most recent reporting period.

A number of other institutional investors have also recently bought and sold shares of the business. Centricity Wealth Management LLC bought a new position in shares of Amgen during the fourth quarter valued at $25,000. Pinney & Scofield Inc. bought a new position in shares of Amgen in the fourth quarter valued at about $26,000. Ritter Daniher Financial Advisory LLC DE raised its holdings in shares of Amgen by 66.2% in the fourth quarter. Ritter Daniher Financial Advisory LLC DE now owns 128 shares of the medical research company's stock valued at $33,000 after buying an additional 51 shares during the last quarter. Synergy Investment Management LLC bought a new position in shares of Amgen in the fourth quarter valued at about $34,000. Finally, Atala Financial Inc bought a new position in shares of Amgen in the fourth quarter valued at about $34,000. Institutional investors and hedge funds own 76.50% of the company's stock.

Amgen Stock Performance

Shares of AMGN stock traded up $3.48 during trading on Friday, reaching $287.02. 5,437,576 shares of the company's stock were exchanged, compared to its average volume of 2,813,486. The company has a quick ratio of 0.95, a current ratio of 1.26 and a debt-to-equity ratio of 9.62. The stock has a market capitalization of $154.33 billion, a PE ratio of 38.02, a PEG ratio of 2.63 and a beta of 0.51. Amgen Inc. has a twelve month low of $253.30 and a twelve month high of $346.85. The firm's fifty day moving average price is $283.46 and its 200-day moving average price is $285.42.

Amgen (NASDAQ:AMGN - Get Free Report) last posted its earnings results on Thursday, May 1st. The medical research company reported $4.90 earnings per share for the quarter, topping analysts' consensus estimates of $4.18 by $0.72. The business had revenue of $8.15 billion for the quarter, compared to analyst estimates of $8.05 billion. Amgen had a return on equity of 176.32% and a net margin of 12.24%. The firm's revenue was up 9.4% compared to the same quarter last year. During the same period in the previous year, the firm earned $3.96 EPS. As a group, sell-side analysts anticipate that Amgen Inc. will post 20.62 EPS for the current year.

Amgen Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Friday, June 6th. Shareholders of record on Friday, May 16th will be issued a $2.38 dividend. This represents a $9.52 dividend on an annualized basis and a yield of 3.32%. The ex-dividend date is Friday, May 16th. Amgen's dividend payout ratio is 86.86%.

Wall Street Analysts Forecast Growth

AMGN has been the subject of a number of research analyst reports. Morgan Stanley reaffirmed an "equal weight" rating on shares of Amgen in a report on Friday, May 2nd. Johnson Rice set a $294.00 price target on Amgen in a report on Wednesday, March 5th. Royal Bank of Canada cut their price target on Amgen from $324.00 to $320.00 and set an "outperform" rating for the company in a report on Friday, May 2nd. Erste Group Bank cut Amgen from a "strong-buy" rating to a "hold" rating in a report on Thursday, May 8th. Finally, Piper Sandler lowered their price objective on Amgen from $329.00 to $328.00 and set an "overweight" rating for the company in a research report on Friday, May 16th. Two investment analysts have rated the stock with a sell rating, twelve have assigned a hold rating, nine have given a buy rating and two have given a strong buy rating to the stock. Based on data from MarketBeat.com, Amgen has a consensus rating of "Hold" and an average target price of $309.22.

Amgen Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.